COMUNICADO: Expertos instan a la acción urgente y mejorar del tratamiento de la infección por Clostridium difficile en Europa (y 2)

Astellas Pharma EMEA realiza operaciones en 40 países de Europa, Oriente Medio y África, y es el centro regional empresarial en EMEA de Astellas Pharma Inc., con sede en Tokio. Astellas es una empresa farmacéutica dedicada a mejorar la salud de las personas de todo el mundo mediante el suministro de fármacos innovadores y fiables. La compañía tiene como objetivo convertirse en una empresa global que combine capacidades extraordinarias de I+D y marketing y continúe creciendo en el mercado mundial farmacéutico. La presencia de Astellas en Europa incluye además un sitio de I+D y tres plantas de fabricación. La compañía cuenta con más de 4.500 empleados en la región EMEA. En el año 2013 Astellas recibió el premio SCRIP Pharmaceutical Company of the Year como reconocimiento de su éxito comercial y desarrollo de gama disponible.

Referencias

1) KA Davies et al. Underdiagnosis of Clostridium difficile across Europe:

the European, multicentre prospective, biannual, point-prevalence study of Clostridium

difficile infection in hospitalised patients with diarrhoea (EUCLID). The Lancet

Infect Dis. 2014;14:1208-19. Disponible en:

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(14)70991-0/fulltext

Último acceso noviembre de 2014.

2) Committee on the Environment, Public Health and Food Safety. Report on the

report from the Commission to the Council on the basis of Member States' reports on

the implementation of the Council Recommendation (2009/C 151/01) on patient safety,

including the prevention and control of HAIs (2013/2022(INI)), European Parliament

2013.

3) European Centre for Disease Prevention and Control. Point prevalence survey

of healthcare-associated infections and antimicrobial use in European acute care

hospitals. Stockholm: ECDC; 2013.

4) Meyer E et al. Associations between nosocomial meticillin-resistant

Staphylococcus aureus and nosocomial Clostridium difficile-associated diarrhoea in 89

German hospitals. J Hosp Infect. 2012;82(3):181-6.

5) UK Health Protection Agency. English national point prevalence survey on

healthcare-associated infections and antimicrobial use, 2011: preliminary data.

London; Health Protection Agency, 2012.

6) European Commission. European hospital survey: benchmarking deployment of

e-health services (2012-2013). 2014. Available at:

http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&cad. Último

acceso noviembre de 2014.

7) Bauer MP et al, for the ECDIS Study Group. Clostridium difficile infection in

Europe: a hospital based survey. Lancet 2011; 377: 63-73.

8) Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile

-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12 Suppl

6:2-18.

9) Adler A, Schwartzberg Y, Samra Z, Schwarts O, Carmeli Y, Schwaber M J and the

Isreali Clostridium difficile diagnostics study group. Trends and changes in

Clostridium difficile diagnostic policies and their impact on the proportion of

positive samples: a national survey. Clin Microbiol Infect. 2014; Doi:

10.1111/1469-0691.12634 (Epub antes de impresión).

10) Updated guidance on the diagnosis and reporting of Clostridium difficile.

Epub. Available at:

https://www.gov.uk/government/publications/updated-guidance-on-the-diagnosis-and-repor

ting-of-clostridium-difficile. Último acceso noviembre de 2014.

11) Wiegand P N, Nathwani D, Wilcox M H, Stephens J, Shelbaya A and Haider S.

Clinical and economic burden of Clostridium difficile infection in Europe: A

systematic review of healthcare-facility-acquired infection. J. Hosp. Infect.

2012;81:1-14.

12) McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, Muder RR,

Lee BY. 2012. The economic burden of Clostridium difficile. Clin Microbiol Infect.

2012;18:282-9.

13) Laqu T, Stefan M S, Haessler S, Higgins T L, Rothberg M B, Nathanson B H,

Hannon N S, Steingrub J S, Lindenauer P K. The impact of hospital-onset Clostridium

difficile infection on the outcomes of hospitalized patients with sepsis. J Hosp Med.

2014;Doi: 10.1002/jhm.2199 (Epub antes de impresión).

14) McMaster-Baxter NL, Musher DM. Clostridium difficile: recent epidemiologic

findings and advances in therapy. Pharmacotherapy. 2007;27:1029-39.1.

15) Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk

factors and management. Nat Rev Gastroenterol Hepatol. 2011;8:17-26.

16) Sunenshine R, McDonald L. Clostridium difficile-associated disease: new

challenges from an established pathogen. Cleve Clin J Med. 2006;73:187-97.

17) Lyytikäinen O, et al. Hospitalizations and Deaths Associated with

Clostridium difficile Infection, Finland, 1996-2004. Emerg Infect Dis. 2009;15:761-5.

18) Soler P, et al. Rates of Clostridium difficile infection in patients

discharged from Spanish hospitals, 1997-2005. Infect Control Hosp Epidemiol.

2008;29:887-9.

19) Vonberg RP, et al. Clostridium difficile in Discharged Inpatients, Germany.

Emerg Infect Dis. 2007;13:179-80.

20) Freeman J, et al. The Changing Epidemiology of Clostridium difficile

Infections. Clin Microbiol Rev. 2010;23(3):529-549.

21) Poutanen SM, et al. Clostridium difficile-associated diarrhoea in adults.

CMAJ. 2004;171:51-8.

22) Kelly CP, et al. Clostridium difficile infection. Ann Rev Med.

1998;49:375-390.

23) Crobach MJ, et al. European Society of Clinical Microbiology and Infectious

Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium

difficile-infection (CDI). Clin Micro Infect. 2009;15:1053-1066.

24) Pepin J, et al. Increasing risk of relapse after treatment of Clostridium

difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-7.

25) Bouza E, et al. Results of a phase III trial comparing tolevamer, vancomycin

and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin

Micro Infect. 2008;14(Suppl 7):S103-4.

26) Lowy I, et al. Treatment with Monoclonal Antibodies against Clostridium

difficile Toxins. N Engl J Med. 2010;362;3:197-205.

27) Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile

infection. N Engl J Med. 2011;364:422-31.

28) Bauer MP, et al. European Society of Clinical Microbiology and Infectious

Disease (ESCMID): treatment guidance document for Clostridium difficile-infection

(CDI). Clin Micro Infect. 2009;15:1067-79.

Photo:

http://photos.prnewswire.com/prnh/20141202/718276-INFOCONTACTO: Si desea más información contacte con: Donna Wright, RuderFinn, dwright@ruderfinn.co.uk, Teléfono: +44(0)20-7438-3085 / Mindy Dooa,Astellas Pharma EMEA., mindy.dooa@astellas.com, Teléfono:+44(0)7826-912-339